![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Grants Approval to Blood-based Companion Diagnostic for Tagrisso
FDA Grants Approval to Blood-based Companion Diagnostic for Tagrisso
October 7, 2016
The FDA approved a companion diagnostic test for Tagrisso (osimertinib), which uses a tissue or blood sample to confirm T790M mutations in patients with metastatic non-small cell lung cancer. The diagnostic, the cobas EGFR Mutation Test v2, was developed by Roche Molecular Systems.
Blood-based testing for the presence of the mutation is recommended only when a tumor biopsy cannot be obtained. Physicians who receive a negative result for the epidermal growth factor receptor T790M mutation with the blood-based test should re-evaluate the feasibility of tissue-based testing to confirm the presence of the mutation, according to AstraZeneca, Tagrisso’s sponsor.
Tagrisso received accelerated approval in November 2015 as a targeted medicine for the treatment of EGFR T790M mutation-positive NSCLC, which has progressed on or after an EGFR tyrosine kinase inhibitor medicine.
Upcoming Events
-
21Oct